Alpha DNA Investment Management’s Merck MRK Stock Holding History

Alpha DNA Investment Management’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,222	Closed	-$1.12M	–	108
2024 Q4	$1.12M	Sell	11,222 -6,598	-37%	-$680K	0.43%	45
2024 Q3	$2.02M	Buy	17,820 +1,254	+8%	+$149K	0.76%	24
2024 Q2	$2.05M	Sell	16,566 -7,034	-30%	-$906K	0.8%	24
2024 Q1	$3.11M	Buy	23,600 +5,450	+30%	+$672K	1.15%	8
2023 Q4	$1.98M	Buy	18,150 +6,263	+53%	+$650K	0.77%	22
2023 Q3	$1.22M	Sell	11,887 -15,971	-57%	-$1.72M	0.5%	38
2023 Q2	$3.21M	Buy	27,858 +15,753	+130%	+$1.79M	1.07%	8
2023 Q1	$1.29M	Buy	12,105 +862	+8%	+$93.1K	0.38%	59
2022 Q4	$1.25M	Sell	11,243 -3,777	-25%	-$386K	0.44%	59
2022 Q3	$1.29M	Buy	15,020 +12,787	+573%	+$1.14M	1.07%	17
2022 Q2	$203K	Buy	+2,233	New	+$198K	0.17%	114
2021 Q2	–	Sell	-3,113	Closed	-$229K	–	430
2021 Q1	$229K	Buy	3,113 +323	+12%	+$23.8K	0.26%	101
2020 Q4	$217K	Buy	+2,790	New	+$213K	0.23%	101

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Alpha DNA Investment Management's MRK Position: Q1 2025 in Review

Alpha DNA Investment Management sold out of Merck (MRK) in Q1 2025, closing a stake of 11,222 shares — an estimated $1.12M sold.

Alpha DNA Investment Management first reported a position in MRK in Q4 2020 and held it in 13 quarters. The position peaked at $3.21M in Q2 2023. 3,447 funds tracked by Wall St. Rank hold MRK as of Q1 2025.

Alpha DNA Investment Management reported no remaining Merck position as of Q1 2025 after selling out during the quarter.
Alpha DNA Investment Management sold 11,222 Merck shares in Q1 2025, an estimated $1.12M.
Alpha DNA Investment Management first reported a position in Merck in Q4 2020 and held it in 13 quarters.
Alpha DNA Investment Management's Merck position peaked at $3.21M in Q2 2023.
3,447 funds tracked by Wall St. Rank held Merck as of Q1 2025.

Based on Alpha DNA Investment Management's 13F filing for Q1 2025, filed 19 May 2025.